InflaRx (IFRX) Revenue & Revenue Breakdown
InflaRx Revenue Highlights
Latest Revenue (Y)
$61.80K
Latest Revenue (Q)
$36.25K
InflaRx Revenue by Period
InflaRx Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | $61.80K | 100.00% |
| 2022-12-31 | - | 100.00% |
| 2021-12-31 | - | 100.00% |
| 2020-12-31 | - | 100.00% |
| 2019-12-31 | - | 100.00% |
| 2018-12-31 | - | -100.00% |
| 2017-12-31 | $231.00K | 100.00% |
| 2016-12-31 | - | 100.00% |
| 2015-12-31 | - | - |
InflaRx generated $61.80K in revenue during NA 2023, up 100.00% compared to the previous quarter, and up Infinity% compared to the same period a year ago.
InflaRx Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-03-31 | $36.25K | 1527.46% |
| 2023-12-31 | $2.23K | -96.34% |
| 2023-09-30 | $60.80K | 100.00% |
| 2023-06-30 | - | 100.00% |
| 2023-03-31 | - | 100.00% |
| 2022-12-31 | - | 100.00% |
| 2022-09-30 | - | 100.00% |
| 2022-06-30 | - | 100.00% |
| 2022-03-31 | - | 100.00% |
| 2021-12-31 | - | 100.00% |
| 2021-09-30 | - | 100.00% |
| 2021-06-30 | - | 100.00% |
| 2021-03-31 | - | 100.00% |
| 2020-12-31 | - | 100.00% |
| 2020-09-30 | - | 100.00% |
| 2020-06-30 | - | 100.00% |
| 2020-03-31 | - | 100.00% |
| 2019-12-31 | - | 100.00% |
| 2019-09-30 | - | 100.00% |
| 2019-06-30 | - | 100.00% |
| 2019-03-31 | - | 100.00% |
| 2018-12-31 | - | 100.00% |
| 2018-09-30 | - | 100.00% |
| 2018-06-30 | - | 100.00% |
| 2018-03-31 | - | -100.00% |
| 2017-12-31 | $231.00K | 100.00% |
| 2017-09-30 | - | 100.00% |
| 2017-06-30 | - | 100.00% |
| 2017-03-31 | - | 100.00% |
| 2016-12-31 | - | 100.00% |
| 2016-09-30 | - | 100.00% |
| 2016-06-30 | - | - |
InflaRx generated $36.25K in revenue during Q1 2024, up 1527.46% compared to the previous quarter, and up Infinity% compared to the same period a year ago.
InflaRx Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| EYPT | EyePoint Pharmaceuticals | $46.02M | $10.52M |
| HOWL | Werewolf Therapeutics | $19.94M | $1.14M |
| OCUP | Ocuphire Pharma | $19.05M | $1.11M |
| IKNA | Ikena Oncology | $9.16M | - |
| STOK | Stoke Therapeutics | $8.78M | $4.89M |
| KZR | Kezar Life Sciences | $7.00M | - |
| KRON | Kronos Bio | $6.29M | $2.37M |
| GBIO | Generation Bio | $5.90M | $4.09M |
| FULC | Fulcrum Therapeutics | $2.81M | - |
| IFRX | InflaRx | $61.80K | $36.25K |
| DSGN | Design Therapeutics | - | - |
| CCCC | C4 Therapeutics | - | - |
| RVPH | Reviva Pharmaceuticals | - | - |
| ABOS | Acumen Pharmaceuticals | - | - |
| INZY | Inozyme Pharma | - | - |
| ERAS | Erasca | - | - |
| PASG | Passage Bio | - | - |
| GLUE | Monte Rosa Therapeutics | - | $4.70M |
| EWTX | Edgewise Therapeutics | - | - |
| SLS | SELLAS Life Sciences Group | - | - |
| ELDN | Eledon Pharmaceuticals | - | - |